Camallergy awarded £1.1m government funding for peanut allergy immunotherapy
March 9, 2021Manufacturing and Production Camallergy, UK, allergy
Camallergy, a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded …
Valo and ImmunoScape collaboration identifies immunogenic peptides for pan-coronavirus vaccine
March 9, 2021Manufacturing and Production COVID-19, Valo Therapeutics, immunoscape, vaccines
Immunotherapy platform developer Valo Therapeutics has successfully completed a collaboration with the biotechnology company ImmunoScape to identify immunogenic peptides for …
Novartis’ canakinumab fails to improve lung cancer survival in Phase III study
March 9, 2021Manufacturing and Production Cancer, Novartis, lung cancer
Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …
CHMP recommends Lilly’s bamlanivimab for COVID-19 patients
March 8, 2021Sales and Marketing COVID-19, EMA, Eli Lilly
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly’s bamlanivimab …
FDA grants Priority Review to Korsuva for CKD-associated pruritis
March 8, 2021Sales and Marketing Cara Therapeutics, FDA, Korsuva
The FDA has accepted and granted Priority Review for the new drug application (NDA) for Cara Therapeutics’ Korsuva (difelikefalin) solution …
NICE recommends £1.79m gene therapy for spinal muscular atrophy in babies
March 8, 2021Sales and Marketing NICE, spinal muscular atrophy
NICE is set to approve a new and potentially curative one-off gene therapy for babies with the rare genetic disorder …
ViiV presents positive long-term data for combined HIV treatment
March 8, 2021Sales and Marketing HIV, ViiV Healthcare
ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …
Roche voluntarily withdraws Tecentriq’s US bladder cancer indication
March 8, 2021Sales and Marketing Cancer, Roche, bladder cancer, tecentriq
Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …
Pharmafile.com’s top 10 news stories of the week
March 5, 2021Medical Communications COVID, COVID-19, COVID-19 vaccine, news roundup, pharma news, roundup
The last week has seen its fair share of COVID-19 vaccine developments; Bharat Biotech’s candidate was found to be 81% …
FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease
March 5, 2021Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis
Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …
Amgen to acquire Five Prime Therapeutics for approximately $1.9bn
March 5, 2021Medical Communications Amgen, Cancer, five prime
Amgen has announced it will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of …
Novartis signs agreement to manufacture CureVac’s COVID-19 vaccine
March 5, 2021Medical Communications COVID-19, CureVac, Novartis, vaccines
CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the …
UK government invests £5m in COVID-19 mRNA vaccine library
March 5, 2021Medical Communications COVID-19, CPI, government, vaccines
The Centre for Process Innovation (CPI) has received a £5 million investment from the UK government, to support the development …
Takeda agree $856m deal with Ovid to take over soticlestat development
March 4, 2021Ovid, Takeda, epilepsy treatment, epiplepsy, soticlestat
Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …
Beyond Batten Disease Foundation partners with Actelion on development of combination treatment
March 4, 2021Actelion, Batten disease, Janssen
Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of …
Bharat Biotech’s COVAXIN jab 81% effective in Phase III trial
March 4, 2021Bharat Biotech, COVID-19, COVID-19 vaccine, Vaccine, bharat
Bharat Biotech’s COVID-19 vaccine candidate has shown an interim efficacy of 81% in a Phase III trial, the company announced …
Hong Kong Baptist University researchers develop drug for EBV-associated cancers
March 4, 2021Cancer, Epstein-barr virus, Hong Kong
Researchers at Hong Kong Baptist University have developed a novel drug with the potential to become a next-generation treatment for …
ConserV and eTheRNA partner on infectious disease vaccines
March 4, 2021ConserV, eTheRNA, vaccines
ConserV Bioscience and eTheRNA immunotherapies have agreed to collaborate on the development of vaccine candidates for infectious diseases. ConserV is …
Pharmafile.com’s weekly COVID-19 news round-up
March 3, 2021Research and Development
The past week has continued to see positive COVID-19 news; COVAX has delivered their first batch of vaccines to Africa, …
ViaCyte and Gore collaborate on new diabetes treatments
March 3, 2021Research and Development Type 1 diabetes, diabetes, diabetes treatment, gore, viacyte
Clinical stage medicine company ViaCyte have extended their collaboration with materials science organisation Gore to develop new candidates for the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
